SeaSpine® Announces Full Commercial Launch of WaveForm® C 3D Printed Interbody System
The Company’s Second Fully Commercialized Interbody System Featuring New WaveForm 3D Printing Technology Addresses an Estimated $200 Million Cervical Market Opportunity.
CARLSBAD, Calif., June 21, 2022 (GLOBE NEWSWIRE) — SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company specializing in surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of the WaveForm C Interbody System.
The WaveForm C interbody system, SeaSpine’s first 3D printed cervical interbody, has the highest strength to porosity ratio compared to other 3D printed structures1 due to its exclusive continuous wave structure. This interbody system responds to a market opportunity of more than $200 million. WaveForm C interbodies feature 65% endplate porosity to aid in early stability2 and 75% body porosity for graft fluidity/compressibility, reduced stiffness, and improved imaging.
“WaveForm C uses a unique sheet-based architecture. Years of research have led to this structure, which balances strength, porosity and surface area, while allowing the fluidity of our best DBM fiber product, OsteoStrand® More. This combination of features delivers what we believe is cutting-edge clinical value with the goal of driving fusion,” said Ryan Pearson, Senior Director of Marketing, Cervical.
WaveForm C is licensed for use in multiple contiguous levels with Shoreline® TruProfile® plating or with Admiral™ anterior cervical plate. The WaveForm C System includes multiple impressions and lordosis options, allowing surgeons to address specific anatomical needs.
“WaveForm C is the most advanced 3D printed cervical interbody on the market.” said Dr. Erik Olssonof UNC Health. “The streamlined design allows for efficient insertion and flexibility with plate placement, while the porosity and surface structure provide an optimal environment for fusion, especially with OsteoStrand® More fiber.”
1O. Al-Ketan, R. Rowshan, RK Abu Al-Rub, Topology-mechanical property relationship of periodic 3D-printed metallic, skeletal, and sheet-based cellular materials, Addit. Fab. 19 (2018) 167–183.
2CN Kelly, et al., Additively Fabricated High Strength Porous Implants with Optimized Mechanical Osseointegration, Acta Biomater. 279 (2021).
About Sea Spine
Sea Thorn (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients with spinal disorders. SeaSpine’s comprehensive procedural solutions include its market-leading FLASH™ navigation, a system designed to improve screw placement accuracy and provide a cost-effective, time-saving and radiation-free solution for surgical navigation, as well as a comprehensive portfolio of spinal and orthobiologic implants to address the diverse product combinations that neurosurgeons and orthopedic spine surgeons need to facilitate spinal fusion in minimally invasive degenerative surgery (MIS) and complex spinal deformity procedures on the lumbar, thoracic and cervical spine. With product development expertise in the areas of advanced optics, software, orthobiologic sciences and spinal implants, SeaSpine can offer its surgeon customers a complete solution to meet the evolving clinical needs of their patients. SeaSpine currently markets its products in the United States and in approximately 30 countries around the world.
SeaSpine cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements based on the company’s current expectations and assumptions. These forward-looking statements include, but are not limited to, statements relating to product design goals and the ability of the underlying products to achieve the design goals, including the highest strength-to-porosity ratio compared to other 3D printed products. masterpieces ; have graft fluidity; decrease stiffness; improve imaging; and to facilitate early stability. Among the factors that could cause or contribute to material differences between the Company’s actual results and the expectations indicated by the forward-looking statements are risks and uncertainties, which include, but are not limited to: the ability of newly launched products to operate as intended and intended and to meet the needs of surgeons and patients, including due to the lack of clinical validation of products in limited commercial launch (or “alpha”); an unexpected delay, including due to new product development and launch support, including due to obtaining regulatory approvals; and other risks and uncertainties more fully described in press releases and the Company’s periodic filings with the Securities and Exchange Commission. The Company’s public filings with the Securities and Exchange Commission are available at www.sec.gov.
You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made. SeaSpine does not intend to revise or update the forward-looking statements set forth in this press release to reflect events or circumstances occurring after the date hereof, except as required by law.
Source: SeaSpine Holdings Corporation